1-(4-(dimethylamino)phenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one | 127034-48-4

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 直链 1,3-二芳基丙烷
• 英文名称: 1-(4-(dimethylamino)phenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
• 英文别名: (E)-1-[4-(dimethylamino)phenyl]-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
• CAS: 127034-48-4
• 化学式: C₂₀H₂₃NO₄
• 分子量: 341.407
• InChiKey: VIFRKOWCKUMHOG-IZZDOVSWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  48
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  3,4,5-三甲氧基苯甲醛 、 二甲氨基苯乙酮 在 sodium hydroxide 作用下， 以 乙醇 为溶剂， 反应 18.0h， 生成 1-(4-(dimethylamino)phenyl)-3-(3,4,5-trimethoxyphenyl)prop-2-en-1-one
  参考文献：
  名称：

  Chalcones: a new class of antimitotic agents

  摘要：

  A series of chalcones was evaluated as antimitotic agents. One of these, (E)-1-(2,5-dimethoxyphenyl)-3-[4-(dimethylamino)phenyl]-2-methyl-2-pr open- 1-one) (73), was found to be an effective antimitotic agent at a concentration of 4 nM in an in vitro HeLa cell test system. When evaluated in experimental tumor models in vivo, this compound exhibited antitumor activity against L1210 leukemia and B16 melanoma.

  DOI：

  10.1021/jm00169a021

文献信息

• Substituted arylcycloalkanes, compositions containing them and use thereof
  申请人：——

  公开号：US20030149072A1

  公开（公告）日：2003-08-07

  Substituted arylcycloalkanes, compositions containing them and use thereof. The present invention relates especially to substituted arylcycloalkanes with therapeutic activity, which may be used such as in oncology.

  被取代的芳基环烷烃、含有它们的组合物及其使用。本发明特别涉及具有治疗活性的取代芳基环烷烃，可用于肿瘤学等领域。
• Chalcones bearing a 3,4,5-trimethoxyphenyl motif are capable of selectively inhibiting oncogenic K-Ras signaling
  作者：Sarah E. Kovar、Cody Fourman、Christine Kinstedt、Brandon Williams、Christopher Morris、Kwang-jin Cho、Daniel M. Ketcha

  DOI：10.1016/j.bmcl.2020.127144

  日期：2020.6

  Ras proteins are small GTPases which regulate cellular proliferation, differentiation, and apoptosis. Constitutively active mutant Ras are expressed in similar to 15-20% human cancers, and K-Ras mutations account for similar to 85% of all Ras mutations. Despite the significance of Ras proteins in refractory cancers, there is no anti-Ras drug available in clinic. Since K-Ras must interact with the plasma membrane (PM) for biological activity, inhibition of the K-Ras/PM interaction is a tractable approach to block oncogenic K-Ras activity. Here, we discovered chalcones 1 and 8 exhibit anti-K-Ras activity, and show that the compounds mislocalize K-Ras from the PM and block oncogenic K-Ras signal output. Also, 1 inhibits the growth of K-Ras-driven human cancer cells. Our data suggest that 1 could be a promising starting point for developing anti-K-Ras cancer drug.
• EDWARDS, MICHAEL L.;STEMERICK, DAVID M.;SUNKARA, PRASAD S., J. MED. CHEM., 33,(1990) N, C. 1948-1954
  作者：EDWARDS, MICHAEL L.、STEMERICK, DAVID M.、SUNKARA, PRASAD S.

  DOI：——

  日期：——
• ARYL-CYCLOALCANES SUBSTITUES ET LEUR UTILISATION COMME AGENTS ANTICANCEREUX
  申请人：Aventis Pharma S.A.

  公开号：EP1453783A1

  公开（公告）日：2004-09-08
• US6887904B2
  申请人：——

  公开号：US6887904B2

  公开（公告）日：2005-05-03